Acquisitions:

1. Mankind Pharma, through its Netherlands subsidiary, to acquire a 70% stake in Belgium-headquartered Armed Cell Therapeutics (ACTx), a developer of next-generation “armed” CAR-T cell therapies for cancer, for €48 Million (~INR511.4 crore).
2. Laurus Labs signed a term sheet to acquire a 60% stake in Montréal-based Galenvs Sciences, a magnetic nanoparticle and DNA/RNA technology company, for US$3.75 Million, strengthening its oligonucleotide CDMO capabilities.
3. Gland Pharma to invest US$21 Million through its US subsidiary for a 60% stake in Novelstar Pharma, a newly formed US entity of the Fosun Pharma group focused on sterile formulations.
4. Gilead Sciences to acquire PepStar Therapeutics’ oral IL-23R inhibitor programme, including lead asset HCXT-2001 for inflammatory bowel disease, for US$1.275 Billion in upfront cash.
5. Shionogi to acquire US rare disease company IntraBio, maker of Aqneursa (levacetylleucine), for US$2 Billion.
6. Viatris to acquire Pacira BioSciences, maker of non-opioid pain therapies Exparel and Zilretta, for about US$1.65 Billion.
7. Merck KGaA to acquire UK-based RNAi company Silence Therapeutics for about US$1.3 Billion, adding siRNA candidate divesiran to its pipeline.
8. Ferring Pharmaceuticals to acquire fertility biotech Gameto, developer of the Fertilo egg maturation technology, for up to US$1.38 Billion.
9. Alcon acquired Neurotech Pharmaceuticals, maker of the approved cell therapy implant Encelto for MacTel, for US$550 Million upfront.

Licensing:

1. Biocon signed a license agreement with Janssen Sciences Ireland clearing commercialisation of Yesintek (ustekinumab), its Stelara biosimilar, in nine more markets including Australia, Brazil, China, South Korea and Mexico.
2. Zylidac Bio, the US biologics subsidiary of Zydus Lifesciences, partnered with Prolific Machines to scale Prolific’s light-controlled biologics manufacturing platform to GMP production.
3. Sanofi and Regeneron expanded their antibody alliance to four long-acting IL-13/IL-4 pathway antibodies for type 2 inflammatory diseases, with US$1 Billion upfront and total value of up to US$8 Billion.
4. Novartis licensed China-based Abogen’s mRNA-encoded CD19×CD3 T-cell engager ABO2203 for autoimmune diseases, in a deal worth up to about US$7.8 Billion.
5. Roche signed a deal worth up to US$813 Million with Zymeworks for ZW209, a DLL3 trispecific T-cell engager for small-cell lung cancer.

Investments/Fund Raising:

1. Even Healthcare (Bengaluru) raised US$50 Million in a Series B led by Khosla Ventures with Alpha Wave, to expand its hospital network.
2. CureBay (rural healthtech) raised about INR100 crore (US$10.6 Million) in a pre-Series C round, with equity led by IvyCap Ventures and debt from Trifecta Capital, Alteria Capital and VentureSoul Partners.
3. Clinics On Cloud (Pune, Health ATMs and preventive screening) raised INR120 crore (US$12.5 Million) in a Series A from Dubai-based Model42, at a INR600 crore valuation.
4. Peptris Technologies (Bengaluru, AI drug discovery) secured INR86 crore (US$9 Million) from the Technology Development Board (TDB) to take AI-discovered drugs towards clinical trials.
5. OMass Therapeutics (UK) raised a US$310 Million Series C led by Bain Capital Life Sciences, with Forbion and Novo Holdings, for its endocrinology and immunology pipeline.
6. Pathos AI raised a US$237 Million Series E led by Bristol Myers Squibb at a US$3 Billion valuation, for its AI-driven oncology pipeline.
7. Matchpoint Therapeutics raised a US$150 Million Series B to take its oral autoimmune drug MPT-062 into the clinic.

1. Aagami VP Godwyn Francis is attending Bio Europe 2026 (November 9–11 | Cologne, Germany) with 23+ one-to-one partnering meetings already scheduled. Only 3 time options remain open; please send your meeting request on the platform at the earliest.
2. Aagami Founder Dinesh Jain held 40+ one-to-one meetings with decision makers during his week-long Japan trip, including BioJapan 2026 (October 7–9 | Yokohama).

Market Stage Assets For Licensing/Partnering

1. Licensing Available: FDA-Cleared Portable MRI & AI Guided Robotics Surgery Platform for Prostate Cancer. Applicable for other indications too. 350+ systems sold and $230M in cumulative orders to date across 32+ U.S. states & 19 countries.
2. Seeking Partner / Distribution: CE-marked single-injection bioresorbable implant (KioMedine ^VS One) for Knee Osteoarthritis (OA). Patented non-animal carboxymethyl-chitosan with unique ROS-scavenging action. One Injection. Delivers 9–12 months of pain relief; proven efficacy in HA/steroid-refractory patients. Marketed across 25 countries.
3. First-in-class, broad-spectrum antimicrobial peptide (Peceleganan / PL-5) targeting bacterial & fungal cell membranes with low resistance potential. Market-approved in China for burn wound infections (Phase 3b complete) and Phase 2-ongoing in the US for Diabetic Foot Infections (DFI).
4. High ROI Opportunity to Partner in another U.S. (California) based medtech revolutionizing medical imaging, diagnosis and robotic surgery for Brain and Head (US FDA cleared). Focus on Strokes and TBI. Secured $23M in sales contracts for 2025 and 2026. Currently raising a $30M Series B, of which $20M is already closed.

[In-Development Stage]

1. Phase 3 stage Erythropoietin (EPO) asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). Seeking strategic partner/investment, and EPO supplier also.
2. Phase 2 Broad-Spectrum Revolutionary Antiviral (PRV Eligible). Includes the Coronavirus family, including SARS-CoV-2 (COVID, Long COVID), RSV, Influenza A (including H5N1 "Bird Flu"), as well as Smallpox/MPOX, Measles and Ebola.
3. Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028-29 market launch timeline.
4. Phase 3-Ready Biological Franchise for Smoking Cessation. 2 Injection dosing regimen with no side effect. Phase 2 completed.
5. Seeking Licensing/Partnering: Biobetters Clinical-stage portfolio of 2nd & 3rd-gen therapeutic enzymes (Phase 1) engineered to address known immunogenicity and short half-life limitations. Targets include PKU, ALL/LBL, and ASS1-deficient solid tumors, featuring extended dosing intervals and strong safety profiles. Estimated market approval ~2029-2030
6. Seeking Licensing/Partnering: Phase 3-Ready Drug safety-optimized to treat Atrial Fibrillation (AF); eliminates 3-day hospital onboarding for outpatient prescribing (dofetilide + mexiletine). FDA protocol reviewed, addressing 33M+ patients global market with >$1B peak sales potential.

For Investment:

1. High ROI Opportunity to Invest in U.S. based MedTech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform for Prostate Cancer (On the market). Currently raising last round - Series C targeting up to $70M. Exit via an IPO, strategic M&A, or private equity buyout.
2. Seeking Investment ($30–$40 Million Series A): High-ROI opportunity in Phase 3-ready cardiovascular drug targeting Atrial Fibrillation with >$1B peak annual sales potential. Funds will be used for Phase 3 clinical trials, CMC manufacturing readiness, and FDA NDA filing. Exit via Strategic M&A or IPO.
3. Seeking Investment (US$ ~3.76 Million raised in 2026): Join Investors such as BIRAC in uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
4. High ROI Opportunity to Invest in another U.S. (California) based medtech revolutionizing medical imaging for Brain and Head (US FDA cleared). Exit via an IPO, strategic M&A, or private equity buyout. Secured $23M in sales contracts for 2025 and 2026. Currently raising a $30M Series B, of which $20M is already closed.

For Acquisition:

1. [URGENT] Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing. Bids under evaluation by Bankruptcy Trustee.
2. Available at a very reasonable price - Mountain View Pharma (MVP) including its PharmaPEG® technology for Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.
3. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

Hope you found the content useful. We welcome your feedback and queries.